Satellos Bioscience publishes Q1 2026 MD&A report for three months ended March 31

  • Satellos Bioscience published MD&A for three months ended March 31, 2026, reporting net loss of USD 9.77 million, widening from USD 6.14 million year earlier on higher R&D tied to SAT-3247 clinical work.
  • Cash, cash equivalents, short-term investments totaled USD 69.91 million at quarter-end, up from USD 27.71 million at Dec. 31, 2025, following a February public offering that raised net proceeds of USD 51.9 million.
  • BASECAMP Phase 2 pediatric DMD study dosed first participant Feb. 12; enrollment remains on track for completion in Q3 2026, with more than 100% of targeted participants identified across active and planned sites.
  • TRAILHEAD long-term adult DMD study protocol submitted to FDA in early Q2 2026; plan calls for up to 30 participants across US and Australia, with updates expected through 2026.
  • Planning continues for a Phase 2 trial in FSHD, with regulatory filings targeted for second half of 2026 in US and Canada.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.